AdvaMed® Advancements: Q2 2026 Report
Explore AdvaMed’s Q2 2026 Report to see how advocacy, member engagement, and policy progress are advancing innovation and strengthening the medtech industry.
Emerging Policy Response Resources
2025 Emerging Policy Response Resources
IEEPA Tariff Refunds Summary – What MedTech Companies Need to Know
After the Supreme Court struck down IEEPA tariffs, CBP launched the CAPE system to process refunds. Here’s what importers need to know about eligibility, submission, and timing.
AdvaMed® Advancements: Q1 2026 Report
Explore AdvaMed®’s Q1 2026 report on medtech policy, regulatory trends, reimbursement, and advocacy driving innovation and patient access.
IEEPA Tariff Refunds Are Coming: What Medtech Needs to Know
The U.S. Supreme Court recently marked a significant shift in the tariff landscape, learn what that means for your organization.
Navigating the ACCESS & TEMPO Models: A Direct Dialogue with CMMI & FDA Leaders
Watch AdvaMed’s® exclusive member-only webinar featuring a direct dialogue with CMS Innovation Center leadership on the newly released ACCESS & TEMPO Model. Attendees will gain critical insights into model performance…
The Supreme Court Struck Down IEEPA Tariffs – What Medtech Needs To Know
The U.S. Supreme Court recently marked a significant shift in the tariff landscape, learn what that means for your organization.
AdvaMed® Advancements: Q4 2025 Report
AdvaMed® Advancements: Q4 2025 Report highlights how unified industry advocacy responded to policy disruption, trade uncertainty, and federal action impacting medtech.
AdvaMed® Advancements: Q3 2025 Report
AdvaMed® Advancements: Q3 2025 Report. Amid an increasingly charged political environment,AdvaMed® remained a steady, persuasive voice for medtech innovation. From mobilizing rapid action on the Section 232 investigation to advancing…
The Economic Impact of the Medical Technology Industry 2024
Explore AdvaMed’s 2024 Economic Impact Report, developed by Frost & Sullivan, highlighting medtech’s vital contributions to the U.S. economy
Tariff-related Litigation Update – 9/12
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.